Cross-Sector entity
Of the tracked stories, 9 of 13 also mention Wall Street Zen, the most common co-covered peer. The 173-day window averages about 0.5 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 4 of those 13, with the remainder spread across 7 other categories.
13 verified stories tracked
Last mentioned: 23h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 9 of 13 also mention Wall Street Zen, the most common co-covered peer. The 173-day window averages about 0.5 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 4 of those 13, with the remainder spread across 7 other categories. Negative sentiment appears in 0% of the tracked stories. BTIG Research appears in 13 tracked Cross-Sector stories published from March 5, 2026 through August 24, 2026. Each carries 2 original sources on average.
Computed from the 13 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BTIG Research. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen issues opposing ratings
Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen downgrades to Hold
Wall Street Zen cut both Klaviyo and Oceaneering International from Buy to Hold in Saturday research notes.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
Klaviyo Q2 earnings
Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
SM Energy quarterly results
SM Energy reported $2.19 earnings per share for the quarter.
Timothy Moran sells 2,380 shares
Average price of $23.76 for $56,548.80; stake falls 3.46% to 66,345 shares. Sale to cover tax withholding obligations.
KMTS stock rises
Shares trade up $1.16 to $23.99 with 373,728 shares of volume versus a 404,856 average.
Alfred Ford Jr. sells 8,681 shares
Average price of $22.61 for $196,277.41; stake falls 6.81% to 118,854 shares. Sale to cover tax withholding obligations.
OII insider sale
SVP Christopher J. Dyer sold 1,200 OII shares at an average price of $47.65 for $57,180.
B. Riley trims BRSP target
B. Riley Financial lowered its BrightSpire Capital target from $7.00 to $6.50 with a buy rating.
JonesTrading reiterates BRSP buy
JonesTrading reissued a buy rating and a $6.50 price objective on BrightSpire Capital.
Weiss upgrades OII
Weiss Ratings raised OII from Buy (B-) to Buy (B).
BrightSpire reports Q2 earnings
BRSP posted EPS of $0.13, missing the $0.15 consensus, with revenue of $48.70 million.
Barclays lifts OII target
Barclays increased its OII price objective from $39.00 to $47.00 with an Equal Weight rating.
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
SaaS and cloud operators are watching Klaviyo as a high-multiple vertical SaaS proxy. Wall Street Zen's Buy-to-Hold cut, after Q2 revenue of $370.58 million and EPS in line, shows how quickly a premium valuation can compress when growth doesn't exceed expectations.
Marketing and AdTech teams relying on Klaviyo face new investor scrutiny after Wall Street Zen cut the stock to Hold despite Q2 revenue of $370.58 million and in-line EPS of $0.19. The downgrade lands as analyst targets diverge while the company trades at a 895.95 P/E, raising questions about martech spending sustainability.
Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Source: dailypolitical.com · themarketsdaily.com
Two Kestra Medical Technologies insiders disclosed routine tax-withholding sales totaling 11,061 shares after a July earnings report that missed consensus. The transactions highlight equity-vesting mechanics, but the company's negative margins and projected losses are a more consequential signal for healthcare partners assessing vendor sustainability.
Source: dailypolitical.com · tickerreport.com
Magnite CEO Michael Barrett sold $2.96 million worth of shares, reducing his stake by 30.7% even as the company posted strong Q1 earnings and analyst upgrades. For adtech and marketing pros, this insider move raises questions about the open web programmatic outlook.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis. Markets digest the calls amid wide analyst disagreement.
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
AeroVironment’s lower FY2027 outlook pours cold water on defense drone growth expectations despite a strong quarter. The EPS midpoint of $3.18 vs. $3.95 consensus raises questions about the pace of U.S. and allied UAV procurement and signals a potential reset in the tactical drone market’s investment thesis.
Source: MarketBeat · dailypolitical.com
Wall Street analyst BTIG reaffirmed a buy rating and $19 target for McGraw Hill (MH), projecting a 107.63% gain from its depressed $9.15 share price. The call highlights deep value in the educational publisher as the entire edtech sector undergoes a post-pandemic correction. With a consensus 'Moderate Buy' and $18.72 target, the stock's extreme undervaluation could reward contrarian edtech investors.
Source: Ticker Report · Daily Political
Guidewire Software reported Q4 CY2025 sales that topped analyst estimates, providing a strong rebuttal to recent analyst downgrades and insider selling concerns. The results highlight the accelerating adoption of Guidewire Cloud, bolstered by major international deals like the Sompo Group expansion.
